AIM to Get Better© at Understanding Dementia Blog#1: Alzheimer's Disease - Where are we with drug treatments?

 

AIM to Get Better© at Understanding Dementia Blog #1


Alzheimer’s Disease: Where are we with drug treatments?

On 10th December, I attended an online webinar, hosted by Alzheimer’s Disease International.

It was their inaugural “End of Year Forecast” webinar, entitled “Translating the Alzheimer's Treatment Revolution into Real World Solutions”

Professor Jeff Cummings is possibly one of the most intelligent humans on the planet yet he explained very complex issues around current and future drug treatments for Alzheimer’s Disease (AD) in a way that even I understood! It probably helped that his amazing accent reminded me of “Deputy Dog” (for those of you old enough to remember the 1970’s cartoon character) and therefore very easy to listen to! I have tried to use the same language he used in my notes below. If you would prefer a more academic overview, you can read the academic paper on which his talk was based by using the link below:

https://alz-journals.onlinelibrary.wiley.com/doi/epdf/10.1002/trc2.12465

ADI have produced their own blog about the event, which includes a link to a recording, so if you would rather read their blog than mine, or watch the actual webinar, click below:

https://www.alzint.org/news-events/news/adi-launches-inaugural-end-of-year-forecast-with-professor-jeff-cummings/


Here are my notes from the webinar:

·          The whole webinar used just one slide, (see below), giving an overview of the 127 drugs for AD currently being tested in clinical trials.

·          The majority of these are currently in phase 2 trials.

·          It currently takes 10 years for drugs to move from phase 1 to phase 3 and approval; it is essential we find a way to reduce this timescale.

·          Most of the progress is currently being made with drugs administered intravenously (IV) or subcutaneously (SC) and one of the challenges is to get these developed into a form that can be taken orally (which was the same with cancer treatment research several decades ago)

·          The trials in the blue area are drugs being developed specifically for neuropsychiatric symptoms (agitation, distressed behaviours, hallucinations). One of these drugs was approved in USA in 2024, which is a major breakthrough in reducing antipsychotic use in dementia care.

·          The trials in the orange area are focussed on symptom reduction and the drugs in the purple area are aimed at slowing disease progression. 2024 has seen major breakthroughs in  the approval of drugs that can slow disease progression, for the first time ever!



© J Cummings; M de la Fleur, PhD, Illustrator. Full publication available at https://doi.org/10.1002/trc2.12465

 

·      The trials with a red box next to them are focussed on Amyloid – specifically, triggering the body’s own immune system to break down the Amyloid plaques. One of the challenges with this is that these drugs don’t just trigger the breakdown of proteins in the brain – it can also cause the breakdown of  proteins in blood vessels, increasing the risk of blood “leaking out” of the blood vessels into the brain. This is most likely to happen if people carry the APOE4 gene (the gene that predicts the risk of AD), If we know who is most vulnerable to experience these side effects, we can take action to reduce the risk.

·      The trials with a dark green square next to them represent trials focussed on the protein Tau. It is currently thought that limiting the build up of Tau in the brain will have far more effect on disease progression than limiting the build up of Amyloid. This is therefore a vital area of research.

·      COMBINATION THERAPY IS COMING! As with treatments for cancer and HIV, it is highly likely that we will soon be using treatments that focus on both Amyloid and Tau.

·      30% of the dots on the graphic represent trials that are “repurposing” drugs. For example, Donepezil and Memantine are being developed as “depot injections” which can be given monthly, for those people who may not remember to take oral medications as prescribed. Parkinson’s drugs and some cancer drugs are being trialled to see if they can be used effectively in AD. This is really important as it will drastically reduce the time to get to phase 3 and approval – don’t need to go through animal testing and phase 1 trials because they have already gone through these phases for a different purpose. 

·      Semaglutide , the drug being used for diabetes and weight loss, is being investigated for its possible effect on AD,  both for its anti-inflammatory and metabolic properties. It has already be shown to a very effective anti-inflammatory in the treatment of kidney disease and heart disease. We will know by the end of 2025 if it will have a positive effect on AD, but it looks very promising.

·      There are even clinical trials going on looking at the potential effect of caffeine (effects on Tau), Nicotine, Cannabinoids (treatment of agitation), Chinese medicine.

·      Use of psychedelic medications is also being trialled on people with PTSD, and people with PTSD and dementia.

 

Diagnostics

·      We are very close to having blood tests to diagnose AD, by looking at levels of Tau, Amyloid and inflammatory markers. This is essential, partly because blood tests are much more accessible, and therefore equitable than scans which are expensive and complex to carry out. Also, many GP’s will mis diagnose AD when the person has another form of dementia, so it will ensure targeted treatments can be given. In USA, the FDA has approved the use of blood tests for eligibility to take part in clinical trials.

 

Genetic testing:

·      Although useful in identifying risk, not useful in diagnostics.

·      Looks for APOE4 gene. If you have 0 copies of the gene, you still have a 15% lifetime risk of developing AD. If you have 1 copy (from one parent) you have 30 - 40% lifetime risk. Risk. If you have 2 copies (one from each parent) your risk is 90% +.

·      Not really helpful to know your risk until we have more effective treatments! There is not really anything you can do about a genetically inherited risk – much more helpful to focus on the 14 reversible risk factors (World Alzheimer’s Report 2024).

 

Final reflections

This was one of the most fascinating updates on dementia I have ever attended, and I came away feeling inspired.

I will definitely be looking out for more ADI webinars! Informative and accessible!

 

Mary-Joy Albutt  26.1.25

©AimtoGetBetter2025

 Please visit our website at: https://aimtogetbetter.com

For more blogs by MJ, please visit: https://maryjoyalbutt.blogspot.com


Comments

Post a Comment

Popular posts from this blog

Aim To Get Better© at Understanding trauma #1: Understanding traumatic memory and why people get "triggered"

Image
Aim to Get Better© at Understanding Trauma blog#1:    TRAUMATIC MEMORY AND WHY PEOPLE GET “TRIGGERED” There are two bits of our brain responsible for memory. First, the hippocampus, which is in the cerebral cortex. The cerebral cortex is the most advanced part of our brain and the most recent to evolve. It is the thinking, logical bit, that enables us to calculate, problem solve, organise incoming information, process it and create new information and ideas from it. It is the part of our brain that enables us to function in complex social groups, by learning that, if I behave in one way, it will initiate one kind of response from another person (for example, if I smile at someone they are likely to smile back), but if I behave in a different way, I am likely to get a different response (for example, if I am aggressive towards someone, they may behave aggressively towards me, or retreat from me). It is where my “impulse control switch” stops me from behaving in ways that coul...
Read more

Aim To Get Better© at Understanding Trauma #2: Learning to Manage traumatic memories / flashbacks

Image
  AIM TO GET BETTER  BLOG #2:   LEARNING TO MANAGE TRAUMATIC MEMORIES / FLASHBACKS   1. Quickly identify when you have been triggered We all experience triggering in different ways. Some people may experience severe anxiety or a panic attack. Some may have a compulsion to run away. Others may suddenly display seemingly uncontrollable anger. For me, a single interaction could cause me to change in an instant from feeling OK and in control to feeling completely overwhelmed, unable to stop crying and having a very strong compulsion to self-harm, or even have suicidal thoughts. At other times, I can go into “freeze” mode – I feel as if I am going under a general anaesthetic; I can still hear voices around me, but I feel so detached I am unable to respond.   Some people may start reliving a memory from the past as if it is actually happening now. The first step in learning to take back control of these situations is to identify how you respond when ...
Read more

AIM to Get Better© at Changing my Mind About My Body: Blog#3:Preparing for my Trek Across the Sahara

Image
  AIM to Get Better ©  at Changing my Mind About my Body Blog #3: Preparing for my Trek Across the Sahara With 6 weeks to go until my trek across the Sahara, raising money for the Alzheimer’s society, I persuaded my husband that it would be an excellent way of training if we booked a holiday in Gran Canaria, so I could practice going up and down the sand-dunes of Mas Palomas. It did, in fact, turn out to be an excellent “dry run” – having spent over £800 on essential kit for the expedition, it was really helpful to test it out and find out what worked and what didn’t. Out of the 6 days spent staying in the nearby resort of Playas de Ingles, I spent 4 days out   walking on the sand dunes.      What did I learn? 1.        In the 4 days spent on the sand dunes, I racked up 52km. Based on the number of pints of lager I drank in the evenings (and days off by the pool), I calculate my fuel consumption to be 10.8 mil...
Read more